Zymeworks entered into a research agreement with XOMA to optimize an antibody. The partnership will leverage Zymeworks’ ZymeCAD™ suite of predictive protein engineering tools and XOMA’s Targeted Affinity Enhancement™ technology.


ZymeCAD molecular simulation platform creates a modeling environment that generates novel physical and chemical insights into protein systems, according to Zymeworks.


 

Previous articleCARBON DIOXIDE TRANSPORT PROTEIN IN MICROALGAE IDENTIFIED
Next articlePfizer to Extend Use of Patient Selection Technology from Monogram